tbuckley/cabot-search huggingface dataset:
Estriol
Authors: Sylvain Fribourg
Journal: JAMA (1978)

<h3>To the Editor.—</h3> The report "Estriol in the Management of the Menopause" (239:1638, 1978) is a most promising preliminary communication. Before the conclusions of the report may be accepted unequivocally, I am of the opinion that a truly double-blind study concerning the use of estriol in the management of menopausal symptoms need be done. The world's literature is replete with data disclosing the efficacy of placebos as well as nonestrogenic compounds in the management of menopausal symptoms. I would strongly hope that a doubleblind study would bear out the conclusions of the aforementioned report. Also, it would be of great interest to note the influence of estriol on the prevention and development of osteoporosis in conjunction with the excellent British studies related to this subject. Finally, I might ask the authors to speculate, should their double-blind study data confirm their most recently reported data, what is the estimate of time
SOUND ULTRASOUND THERAPY
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
To Exhume or Not to Exhume!
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Pocket Text-Book of Chemistry and Physics.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Livedo reticularis in patients with parkinsonism receiving amantadine
Authors: C. N. Shealy
Journal: JAMA (1970)

Asymptomatic livedo reticularis has appeared in ten of 18 female patients with parkinsonism treated with amantadine hydrochloride. Although no serious effects have been seen to date, a livedo reticularis type manifestation has been associated at times with serious collagen disorders such as periarteritis nodosa and lupus erythematosus. Although amantadine has distinct beneficial effects in parkinsonism, long-term use should be viewed with some caution.
Reversible orthostatic hypotension of pernicious anemia
Authors: G. E. Johnson
Journal: JAMA (1987)

IN 1980, White et al<sup>1</sup>published a case report that suggested that pernicious anemia could induce a reversible state of orthostatic hypotension, in the absence of other neuropathic signs. This index case was embraced as proved, and incorporated into texts and medical references,<sup>2</sup>despite the following limitations: (1) the observation was never confirmed by other observers, (2) the period of follow-up was only two months and did not preclude the possibility of relapse or fluctuation of signs and symptoms, and (3) the case history included findings that some argue reflect the presence, albeit subtle, of concomitant peripheral neuropathy. In the same year a patient was seen in our facility with orthostatic hypertension. The clinical course of this patient confirms the relationship proposed by White et al and strengthens their observation by demonstrating reproducibility of the phenomenon and the subsequent persistence of remission after appropriate therapy for 24 months.
Enhancing Professionalism
Authors: P. Preston Reynolds
Journal: Annals of Internal Medicine (1994)

Letters15 October 1994Enhancing ProfessionalismP. Preston Reynolds, MD, PhDP. Preston Reynolds, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-8-199410150-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:I agree with Seifer and colleagues that we must consider the broader context of health care delivery when determining how best to preserve and enhance professional values, attitudes, and behaviors [1, 2]. These professional values, attitudes, and behaviors are learned and reinforced explicitly through formal educational structures (for example, bedside rounds, lectures, and seminars) and implicitly through the influence of role models, mentors, and the “silent curriculum.” Perhaps most important is the cultural context of medicine, with its socialization pressures and internal rewards.Academic medical centers have a unique culture that combines research, the delivery of specialized patient ...References1. Reynolds PP. Reaffirming professionalism through the education community. Ann Intern Med. 1994; 120:609-14. Google Scholar2. Reynolds PP. Professionalism and health care reform: Can we preserve quality, compassion, competency, and trust? In: Majumdar SK, Rosenfeld LM, Nash DB, Audet AM, eds. Medicine and Health Care into the 21st Century. Easton, Pennsylvania: The Pennsylvania Academy of Science; 1994 (In press). Google Scholar3. Emanuel EJ. Managed competition and the patient–physician relationship. N Engl J Med. 1993; 329:879-82. Google Scholar4. Foreman S. Social responsibility and the academic medical center: building community-based systems of the nation's health. Acad Med. 1994; 69:97-102. Google Scholar5. Rogers DE. On trust: a basic building block for healing doctor/patient interactions. Pharos. 1994; Spring:2-6. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 October 1994Volume 121, Issue 8Page: 625-626KeywordsBehaviorHealth careMedical educationPatientsPublic policy ePublished: 15 August 2000 Issue Published: 15 October 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Compelled medical treatment of pregnant women
Authors: D. A. Ruley
Journal: JAMA (1989)

<h3>To the Editor. —</h3> In his reply<sup>1</sup>to my letter,<sup>2</sup>Dr Nelson noted my exception to his statement that the criminal law historically does not recognize the killing of a fetus in utero as homicide. I now wish to reaffirm that historically the criminal law did recognize the killing of a fetus in utero as homicide and also take additional exception to his reply by demonstrating its superficiality as well as his error. Dr Nelson, in his reply, argued that he cited "three modern (ie, since 1980) appellate court opinions" for his position and added the following: One of these opinions clearly stated that this rule 'has been accepted as the established law in every American jurisdiction that has considered the question' and cited no fewer than ten recent appellate cases to this effect. Another stated that at common law `the killing of a fetus was not murder
THE NOBEL AWARDS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rubella Reinfection
Authors: HENRY TRAVERS
Journal: Annals of Internal Medicine (1973)

Comments and Corrections1 April 1973Rubella ReinfectionHENRY TRAVERSHENRY TRAVERSSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-78-4-620_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Dr. Wilkins and her colleagues report (Ann Intern Med 77:930-932, 1972) a case of clinically apparent reinfection rubella in a naturally immune woman. Hankenes and Haram (1) reported a similar case in a gravid woman. Prior reports by Northrup (2) Strannegard (3), and Boué (4) stress the recurrence of clinical disease. Serologic evidence of reinfection after natural and vaccine-induced immunity has also been well documented (5, 6).The significance of these findings on rubella-induced embryopathy is unclear. Rubella virus has been isolated from the products of conception of vaccinated women reinfected by wild-type virus during gestation (2),...References1. HAUKENES G and HARAM K: Clinical rubella after reinfection (letter). N Engl J Med 287:1204, 1972 CrossrefMedlineGoogle Scholar2. NORTHRUP R, GARDNER W, and GEITTMANN W: Rubella reinfection during early pregnancy. A case report. Obstet Gynecol 39:524-526, 1972 MedlineGoogle Scholar3. STRANNEGARD O, HOLM S, and HERMODSSON S: Case of apparent reinfection with rubella (letters). Lancet 1:240-241, 1970 CrossrefMedlineGoogle Scholar4. BOUÉ A, NICOLAS A, and MONTAGON B: Reinfection with rubella in pregnant women. Lancet 1:1251-1253, 1971 CrossrefMedlineGoogle Scholar5. HORSTMANN D, LIEBHABER H, and LE BOUVIER G: Rubella: reinfection of vaccinated and naturally immune persons exposed in an epidemic. N Engl J Med 283:771-778, 1970 CrossrefMedlineGoogle Scholar6. CHANG T: Recurrent viral infection (reinfection). N Engl J Med 284:765-773, 1971 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: HENRY TRAVERS PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1973Volume 78, Issue 4Page: 620-621KeywordsImmunityPregnancyRubella ePublished: 1 December 2008 Issue Published: 1 April 1973 PDF downloadLoading ...
Abstract 3: Discovery and optimization of small molecule Bax activators for cancer therapy
Authors: Gang Liu, Hyejin Kim, Chunyong Ding, Zhuo Yu, Hong Wang, Haiying Chen, Qiang Shen, Jia Zhou
Journal: Cancer Research (2019)

Abstract Bax, an indispensable executioner protein of B-cell lymphoma 2 (Bcl-2) family, plays a pivotal role in controlling the mitochondrial dysfunction and apoptosis in normal and cancer cells. High throughput screening to combat the nicotine-induced Bax phosphorylation at serine 184 (S184) to activate the proapoptotic function of Bax has revealed compound SMBA1 as a promising Bax direct activator as we previously reported. Initial medicinal chemistry campaign by choosing SMBA1 as a lead compound for breast cancer treatment resulted in the identification of compound CYD-2-11 with low micromolar IC50 values against MDA-MB-231 and MCF-7 as well as in vivo inhibitory effects against MDA-MB-231 xenograft tumor growth. Herein, we report the comprehensive structural optimization based on CYD-2-11 as the lead by introducing various alkylamino side chains to have a deeper access to S184 pocket and replacing carbon atoms with nitrogen as well as reducing the nitro group of 9H-fluorene scaffold to construct diverse derivatives for enhanced drug properties. CYD-4-61 and GL0385 have been discovered as the most potent anti-breast cancer agents with submicromolar IC50 values of 0.34 and 0.33 µM against MDA-MB-231 as well as 0.65 and 0.26 µM against MCF-7, respectively. More importantly, these drug candidates exhibited significant in vivo efficacy suppressing xenograft tumor growth by activating Bax to induce cancer cell apoptosis with the potential to overcome resistance against Adriamycin (ADR) in breast cancer. This work was supported by Breast Cancer Research Program (BCRP) Breakthrough Award BC160038 (to J.Z.) and BC160038P1 (to Q.S.) from the Department of Defense (DoD). Citation Format: Gang Liu, Hyejin Kim, Chunyong Ding, Zhuo Yu, Hong Wang, Haiying Chen, Qiang Shen, Jia Zhou. Discovery and optimization of small molecule Bax activators for cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3.
Effect of Epinephrine on the Renal Circulation Angiographic Observations
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).
Authors: Fairooz F. Kabbinavar, Nazy Zomorodian, Matthew Rettig, Faraz Khan, Daniel Reif Greenwald, Brian DiCarlo, Sheldon J. Davidson, Ravindranath Patel, Lalita Pandit, Rosh Chandraratna, Martin Sanders
Journal: Journal of Clinical Oncology (2014)

169 Background: IRX4204 is a potent, selective, oral small compound agonist of retinoid X receptor (RXR) nuclear receptor pathways. In preclinical studies IRX4204 synergizes with insulin-like growth factor binding protein-3, to induce apoptosis in human prostate cancer cells and was effective in reducing human prostate tumor burden in a murine xenograft model. The only prostate cancer patient in a phase I trial of IRX4204 trial manifested a sustained greater than 90% prostate-specific antigen (PSA) reduction and a PR lasting over seven months. These findings led to the current open label phase II trial of IRX4204 to evaluate safety and activity or futility, for treatment of advanced castration-resistant metastatic prostate cancer (CRPC). Methods: The trial enrolled 23 men with metastatic CRPC, who had failed a taxane or declined chemotherapy, with ECOG 0-2 with evidence of biochemical or radiographic progression on bone scan, CT and/or MRI. Patients continued with androgen blockade and had to have adequate organ function. Patients were deemed to have demonstrated benefit of IRX4204 treatment if they had PFS greater than 56 days, and/or a 50% PSA decrease, and/or PR or CR by RECIST. Futility defined as four or fewer patients demonstrating benefit in the planned enrollment of 37 patients. Patients received IRX4204 (20 mg/orally daily). PSA was checked Q4 weeks and radiographic assessments Q8 weeks. Radiographic, not PSA progression, was used to determine progression. Results: IRX4204 was well tolerated for up to 11 months. No drug related serious adverse events (SAE) have occurred. Manageable decreases in the thyroid-stimulating hormone (TSH) and increases in triglycerides, both known adverse effects of RXR agonists, have been observed. Protocol defined patient benefit was observed in 13 out of 23 (57%) patients. Progression-free survival (PFS) more than 56 days observed in 13 out of 23 (57%). PFS more than 112 days observed in 9 out of 23 (39%), range 113 to 330 days. PSA 50% response occurred in 3 out of 23 (13%), including one additional PSA 90% response. No objective responses have occurred. Conclusions: This study demonstrates that IRX4204 treatment of taxane-resistant CRPC is well tolerated, and provides an activity signal warranting further evaluation of IRX4204 as a treatment for chemo-refractory CRPC. Funding: Supported by Io Therapeutics, Inc. 1805 East Garry Ave., Suite 110, Santa Ana, 92705. Clinical trial information: NCT01540071.
Error in Figure.
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
“Saving” Bonnie
Authors: Kathleen Bartholomew
Journal: JAMA Internal Medicine (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Intrapleural Insufflation of Dicetyl Phosphate to Promote Pleural Symphysis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal